Applications Submitted to FDA and EMA for Maintenance Rucaparib in Advanced Ovarian Cancer
Cancer Network,
A supplement biologics license and a Type II variation were submitted to the FDA and European Medicines Agency, respectively…
Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status
OncLive,
Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy…
First-Line Rucaparib Maintenance Improves PFS in Ovarian Cancer, Regardless of HRD Status
Cancer Network,
Rucaparib (Rubraca) significantly improved progression-free survival (PFS) when used as a first-line maintenance for patients…